Epinastine hydrochloride for atopic disease

被引:12
|
作者
Fraunfelder, FW [1 ]
机构
[1] Oregon Hlth Sci Univ, Casey Eye Inst, Natl Registry Drug Induced Ocular Side Effects, Portland, OR 97239 USA
来源
DRUGS OF TODAY | 2004年 / 40卷 / 08期
关键词
D O I
10.1358/dot.2004.40.8.850470
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Atopic conditions include allergic rhinitis, atopic eczema, allergic conjunctivitis and asthma. Doctors and patients can choose from a variety of antiallergy medications, testifying that no one medication will suffice to treat all symptoms and that each has a different side-effect profile. Antiallergy medications target histamine receptors, as histamine release contributes to the unpleasant symptoms of itching, tearing, runny nose and skin urticaria. The ideal antihistamine would control the symptoms of atopic disease but cause very few side effects. Traditionally, unwanted effects include drowsiness and somnolence due to CNS depression, and digestive tract problems such as loss of appetite, nausea, vomiting and constipation or diarrhea. Some antihistamines also have anticholinergic effects that are mediated by muscarinic receptors. These atropine-like actions, which can affect the cardiovascular system, are sufficiently prominent in some drugs to be manifest during clinical usage. Epinastine hydrochloride minimally penetrates the blood/brain barrier and has almost no effect on the muscarinic receptors. This drug is marketed as having very few CNS-depressant side effects, few drug interactions and gastrointestinal side effects, and a low risk of cardiotoxicity. (C) 2004 Prous Science. All rights reserved.
引用
收藏
页码:677 / 683
页数:7
相关论文
共 50 条
  • [1] Distribution to the skin of epinastine hydrochloride in atopic dermatitis patients
    Toyoda, Masahiko
    Nakamura, Motokazu
    Nakagawa, Hidemi
    EUROPEAN JOURNAL OF DERMATOLOGY, 2007, 17 (01) : 33 - 36
  • [2] Suppressive activity of epinastine hydrochloride on eosinophil activation in vitro
    Mochizuki, Yu-Ichiro
    Furuta, Atsuko
    Furuya, Ayako
    Kanai, Ken-Ichi
    Asan, Kazuhito
    Suzaki, Harumi
    IN VIVO, 2008, 22 (01): : 13 - 20
  • [3] Epinastine inhibits eosinophil chemotaxis and adhesion molecules in atopic dermatitis
    Matsukura, M
    Yajima, A
    Yamazaki, F
    Yudate, T
    Yamada, H
    Tezuka, T
    SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY, 2003, 16 (06): : 405 - 410
  • [4] A VALIDATED HPLC METHOD FOR SEPARATION AND DETERMINATION OF EPINASTINE HYDROCHLORIDE ENANTIOMERS
    Saleh, Ola A.
    El-Azzouny, Aida A.
    Badawy, Amr M.
    Aboul-Enein, Hassan Y.
    JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES, 2010, 33 (03) : 413 - 422
  • [6] In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses
    Minami, Takahiro
    Ishida, Waka
    Kishimoto, Tatsuma
    Nakajima, Isana
    Hino, Shiori
    Arai, Ritsuko
    Matsunaga, Toru
    Fukushima, Atsuki
    Yamagami, Satoru
    PLOS ONE, 2019, 14 (01):
  • [7] Attenuating effect of epinastine hydrochloride on the function of leptin in patients with allergic rhinitis
    Shino, M.
    Kanei, A.
    Furuta, A.
    Kanai, K.
    Asano, K.
    Suzaki, H.
    ALLERGY, 2011, 66 : 692 - 692
  • [8] FORMULATION DEVELOPMENT AND EVALUATION OF pH TRIGGERED IN SITU OPHTHALMIC GEL OF EPINASTINE HYDROCHLORIDE
    Shaikh, Azmat
    Farheen, Talat
    Shahi, Sadhana
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2016, 7 (03): : 1131 - 1138
  • [9] Modulation of Eosinophil Survival by Epinastine Hydrochloride, an H1 Receptor Antagonist, In Vitro
    Watase, Fumitaka
    Watanabe, So
    Kanai, Ken-Ichi
    Yamada, Naohiro
    Sakaue, Satoshi
    Asano, Kazuhito
    Hisamitsu, Tadashi
    Suzaki, Harumi
    IN VIVO, 2008, 22 (06): : 687 - 691
  • [10] Effects of epinastine hydrochloride on cholinergic neuro-effector transmission in canine tracheal smooth muscle
    Takahashi, N
    Aizawa, H
    Inoue, H
    Matsumoto, K
    Nakano, H
    Hirose, T
    Nishima, S
    Hara, N
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 358 (01) : 55 - 61